A Phase 2, Multicenter, Randomized, Double-blind, Active- and Placebo-controlled Trial of the Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2019
Price : $35 *
At a glance
- Drugs OPC 64005 (Primary) ; Atomoxetine
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 02 Jan 2019 Status changed from active, no longer recruiting to completed.
- 16 Aug 2018 Planned End Date changed from 1 Aug 2018 to 1 Nov 2018.
- 16 Aug 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Nov 2018.